Clinical trials: sponsored by Hutchmed
- Lead sponsor (exact) Hutchmed
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Healthy Participants
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants.
- Trial name
- NCT07643272
- Testing
- HMPL-760, Rabeprazole and HMPL-760
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Health, Subjective
The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets
Primary objective： 1. To evaluate the effect of Itraconazole ( CYP3A and P-gp inhibitors) on HMPL-453 pharmacokinetics(PK) in healthy subjects 2.
- Trial name
- NCT07697157
- Testing
- HMPL-453 with Itraconazole, HMPL-453 with Rifampin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Mass Balance Study
Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects
To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of [14C]HMPL-453
- Trial name
- NCT07644442
- Testing
- HMPL-453
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Healthy
Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans
Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after…
- Trial name
- NCT07331194
- Testing
- HMPL-523 Acetate Tablets (Test Formulation), HMPL-523 Acetate Tablets (Reference Formulation)
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Healthy
Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets
This is a single-center, open-label, randomized, three-period, six-sequence study to evaluate the effect of food (high-fat and low-fat) on the PK of HMPL-523.
- Trial name
- NCT07348133
- Testing
- HMPL-523
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Mass Balance Study
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of [14C]HMPL-306
- Trial name
- NCT06671873
- Testing
- 100 µCi [14C] HMPL-306
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Imumune Thrombocytopenia(ITP) Human Mass Balance
Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of [14C]HMPL-523 suspension
- Trial name
- NCT05781906
- Testing
- HMPL-523, 150 µCi [14C]HMPL-523
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Relapsed or Refractory Lymphoma
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
- Trial name
- NCT05602597
- Testing
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Intrahepatic Cholangiocarcinoma
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
- Trial name
- NCT05930119
- Testing
- HMPL-453, Rabeprazole
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Renal Impairment
Fruquintinib Renal Impairment Study
A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
- Trial name
- NCT05216354
- Testing
- Fruquintinib
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Relapsed or Refractory Lymphoma
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of…
- Trial name
- NCT05720767
- Testing
- HMPL-523, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Relapsed or Refractory Lymphoma
HMPL-523 Food Effect and Proton Pump Inhibitor Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
- Trial name
- NCT05571787
- Testing
- HMPL-523, Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Hepatic Impairment
Fruquintinib Hepatic Impairment Study
An Open-label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
- Trial name
- NCT05216367
- Testing
- Fruquintinib
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Metastatic Colorectal Cancer
Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
- Trial name
- NCT05368805
- Testing
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hutchmed